Agios制药 AGIO 深 沪
交易中 09-30 10:38:00 美东时间
39.3343
+0.064
+0.16%
华盛通- 最 高39.59
- 今 开39.44
- 成交量 4.39万股
- 最 低 38.76
- 昨 收 39.27
- 总市值 22.85亿
- 52周最高 62.58
- 市盈率 静 3.38
- 换手率 0.00%
- 52周最低 23.415
- 委 比 83.91%
- 总股本 5810.15万
- 历史最高 138.85
- 量 比 0.61
- 振 幅 2.11%
- 历史最低 15.77
- 每 手 1
- 风险率 7.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅90.8%！Aris Mining获Canaccord Genuity升目标价至17美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Aris Mining"买入"评级，目标价从16.5美元升至17美元；花旗：维持Docusign"买入"评级，目标价从110美元升至115美元
09-05 09:40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Bone Biologics (NASDAQ:BBLG) shares increased by 30.4% to $2.7 during ...
09-04 20:08
Agios Pharmaceuticals shares are trading lower after the company said the FDA extended the PDUFA goal date for PYRUKYND by three months to Dec. 7.
Agios Pharmaceuticals shares are trading lower after the company said the FDA e...
09-04 19:49
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
Agios Pharmaceuticals announced that the FDA has extended the PDUFA goal date for PYRUKYND's sNDA for treating adult patients with alpha or beta-thalassemia by three months, from September 7, 2025, to December 7, 2025. The extension followed Agios' submission of a proposed REMS to address hepatocellular injury risks, without new efficacy or safety data. Agios remains confident in PYRUKYND's benefit-risk profile. The sNDA is supported by Phase 3 E...
09-04 11:00
Saudi Food And Drug Authority Approves Agios' PYRUKYND For Adults With Thalassemia
First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and
08-05 04:22
Agios Pharma’s PYRUKYND Approved by Saudi Authority
An update from Agios Pharma ( ($AGIO) ) is now available. Agios Pharmaceuticals...
08-05 02:18
Agios Pharmaceuticals shares are trading higher amid reports of Pyrukynd patient deaths.
Agios Pharmaceuticals shares are trading higher amid reports of Pyrukynd patien...
08-04 23:33
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
Agios Pharmaceuticals announced that the Saudi Food and Drug Authority (SFDA) has approved PYRUKYND® (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia. This marks the first regulatory approval for PYRUKYND in thalassemia under the SFDA’s Breakthrough Medicines Program. Agios partnered with NewBridge Pharmaceuticals to manage PYRUKYND’s commercialization in the Gulf Region. The approval is based on results from the Ph...
08-04 20:01
